文献速递创伤骨科骨质疏松与代谢性骨病

老年人群二级骨折预防中启动治疗的有效性:日本晚期人群骨折骨质疏松数据库研究(J-BOLD)——一项随机目标试验的模拟

Effectiveness of treatment initiation for secondary fracture prevention in the older population: Japanese Bone-fracture Osteoporosis in Late-stage population Database study (J-BOLD) - emulation of a randomized target trial.
PubMed 文献 · Osteoporos Int · 2025-09-04

本研究利用日本2014—2022年行政索赔数据模拟随机目标试验,评估≥75岁骨质疏松性骨折患者骨折后3个月内启动并持续≥6个月骨质疏松药物治疗对二级骨折的预防效果。经高维倾向评分匹配后分析53,436人,结果显示治疗与任何骨折及髋部骨折风险降低相关,男性与女性均获益。

要点

  • 骨折后3个月内启动并持续≥6个月骨质疏松药物,与≥75岁人群任何骨折和髋部骨折风险降低相关。
  • 持续≥6个月治疗时,男性任何骨折HR 0.71、髋部骨折HR 0.56;女性任何骨折HR 0.78、髋部骨折HR 0.60。
  • 持续≥12个月治疗时,男性任何骨折HR 0.65、髋部骨折HR 0.59;女性任何骨折HR 0.74、髋部骨折HR 0.55。

核心结论

  • 骨折后早期启动并持续使用骨质疏松药物,与≥75岁男性和女性二级骨折风险降低相关,髋部骨折尤其明显。

研究设计与样本

  • 采用目标试验模拟设计,模拟随机对照试验,使用日本2014—2022年行政索赔数据。
  • 203,534例近期骨质疏松性骨折患者中,40,063例在3个月内启动骨质疏松药物(暴露组),163,471例未启动(对照组)。
  • 经高维倾向评分匹配识别53,436人进行分析,其中暴露组26,718例、对照组26,718例。
  • 研究人群平均年龄83.7岁,女性占77.9%。
  • 采用Cox回归估计任何部位及特定部位二级骨折的风险比(HR)和95%置信区间(CI)。

主要发现

  • 治疗≥6个月后,任何骨折HR在男性为0.71(95%CI:0.60-0.86)、女性为0.78(95%CI:0.71-0.88)。
  • 治疗≥6个月后,髋部骨折HR在男性为0.56(95%CI:0.36-0.80)、女性为0.60(95%CI:0.49-0.72)。
  • 治疗≥12个月后,任何骨折HR在男性为0.65(95%CI:0.48-0.82)、女性为0.74(95%CI:0.68-0.85)。
  • 治疗≥12个月后,髋部骨折HR在男性为0.59(95%CI:0.19-0.84)、女性为0.55(95%CI:0.44-0.69)。

临床怎么用

  • 原文结论指出,早期启动并持续使用骨质疏松药物与≥75岁人群二级骨折风险降低相关,尤其髋部骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Initiating osteoporosis medication within 3 months after fracture reduces secondary fractures, particularly hip fractures, in individuals aged ≥ 75 years. This finding highlights the importance of early and sustained treatment in older populations. PURPOSE: To evaluate the efficacy of initiating osteoporosis medication within 3 months after a fracture and continuing it for at least 6 months in preventing secondary fractures among individuals aged ≥ 75 years. METHODS: This study used a targeted trial design, emulating a randomized controlled trial with Japanese administrative claims data from 2014-2022. Among 203,534 individuals with recent osteoporotic fractures, 40,063 initiated osteoporosis medication within 3 months (exposed), while 163,471 did not (controls). High-dimensional propensity score matching identified 53,436 individuals (26,718 exposed and 26,718 controls) for analysis. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for secondary fractures at any and specific sites. RESULTS: The study population had a mean age of 83.7 years and included 77.9% women. After ≥ 6 months of treatment, HRs for any fracture were 0.71 (95% CI: 0.60-0.86) in men and 0.78 (95% CI: 0.71-0.88) in women. For hip fractures, HRs were 0.56 (95% CI: 0.36-0.80) in men and 0.60 (95% CI 0.49-0.72) in women. After ≥ 12 months of treatment, HRs for any fracture were 0.65 (95% CI: 0.48-0.82) in men and 0.74 (95% CI: 0.68-0.85) in women. For hip fractures, HRs were 0.59 (95% CI: 0.19-0.84) in men and 0.55 (95% CI: 0.44-0.69) in women. CONCLUSION: Early initiation and sustained use of osteoporosis medication significantly reduced the risk of secondary fractures, particularly hip fractures, in men and women aged ≥ 75 years.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Tsukamoto M, Hamasaki T, Okimoto N, et al. Effectiveness of treatment initiation for secondary fracture prevention in the older population: Japanese Bone-fracture Osteoporosis in Late-stage population Database study (J-BOLD) - emulation of a randomized target trial. Osteoporos Int. 2025. PMID: 40903594. doi:10.1007/s00198-025-07687-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。